25 November 2014
Dechra® Pharmaceuticals PLC
("Dechra" or "the Company")
Director / PDMR Shareholding
Dechra Pharmaceuticals PLC has been notified that, today, Ian Page (Chief Executive Officer) has transferred 250,000 ordinary shares in the Company to his spouse, Linda Page, for nil consideration.
Following this transfer, Ian Page's, beneficial interest in the Company remains unchanged, being 955,701 shares, which represents 1.09% of the current issued share capital.
For further information, please contact:
Zoe Goulding, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and relates products business. Our expertise is in the development, manufacture and sales and marketing of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.